TRAABA24 is a pilot project led by Bina Therapeutics to tackle a rare disease that impacts 1-3 people per million every year.
TRAABA24 emerged as a promising therapeutic candidate for Pseudomyxoma Peritonei (PMP) through advanced computational research, high-throughput drug screening and molecular docking simulations. It’s derived from an FDA-approved drug with an exceptional safety profile and demonstrates strong binding to critical targets implicated in Pseudomyxoma Peritonei progression. Our computational studies translated positively in vitro cell lines derived from PMP patients but in order to be effective we are optimizing the formulation to address the harsh terrain of the tumor microenvironment in PMP patients.
We are currently undertaking preclinical research and development. Whilst early indications are positive it’s important for us to validate a meaningful impact will be experienced in PMP patients. IF it is, we will be able to submit an application to the UK regulatory body for it’s approved use. We aim to achieve this milestone within 2025 followed by FDA approval towards 2026.
Click here to track our progress or consider subscribing for updates.
Our preclinical work involves identifying new and innovative delivery methods, which includes, enteric capsules, intraperitoneal suspension, and an exploratory non-invasive approach. During this time we will be configuring dosing regimes with comparative analysis against standard of care and side effects.
There are plenty of ways to get involved, you can share our story, join our fundraising efforts or consider working with us if you are a researcher.
There are some wonderful charities and support groups setup to help PMP patients navigate the complex journey after receiving a diagnosis. If you’re looking for more information about their work, someone to talk to or share your story with consider reaching out to the organizations below:
